TREM2 as a Potential Immune-Related Biomarker of Prognosis in Patients with Skin Cutaneous Melanoma Microenvironment

Table 2

The TREM2 expression and clinicopathological variables association in groups.

Characteristic	Low TREM2 expression	High TREM2 expression	value
	234	234
Age, (%)			1.000
≤60	124 (27%)	125 (27.2%)
>60	106 (23%)	105 (22.8%)
Gender, (%)			0.342
Female	84 (17.9%)	95 (20.3%)
Male	150 (32.1%)	139 (29.7%)
Race, (%)			0.771
Asian	7 (1.5%)	5 (1.1%)
Black or African American	0 (0%)	1 (0.2%)
White	222 (48.5%)	223 (48.7%)
BMI, (%)			0.050
≤25	53 (21.3%)	31 (12.4%)
>25	81 (32.5%)	84 (33.7%)
T stage, (%)			0.629
T1	24 (6.6%)	17 (4.7%)
T2	40 (11.1%)	38 (10.5%)
T3	42 (11.6%)	48 (13.3%)
T4	80 (22.2%)	72 (19.9%)
N stage, (%)			0.297
N0	119 (29%)	115 (28%)
N1	39 (9.5%)	35 (8.5%)
N2	18 (4.4%)	31 (7.5%)
N3	26 (6.3%)	28 (6.8%)
M stage, (%)			0.852
M0	208 (47.3%)	208 (47.3%)
M1	11 (2.5%)	13 (3%)